The model generates backbone shape, amino acid choice and side-chain packing together when designing peptides that bind a target pocket.
Recap by typeshit. Post by Biology+AI Daily on X.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Covers the 28.3% versus 25.0% weight loss figures, the 12% who quit at 9 mg in TRIUMPH-2, and why online vials sold as Reta aren't the trial drug.
Across nearly 44,000 matched patients over 65, GLP-1 users had a 45% lower death risk, researchers report, though they also saw more osteoporosis and retinopathy.
Loading…